AbbVie's Elagolix May Be Cost Effective, But Will Test Health Budgets – ICER
Executive Summary
Third-party value assessment organization says AbbVie/Neurocrine's elagolix would be cost effective for endometriosis and associated pain, using a placeholder price of $7,000 per year. But the cost would be substantial for health budgets given the broad prevalence of the condition.
You may also be interested in...
AbbVie Prices Oral Endometriosis Drug Orilissa In Value Range, Focusing On Access
In addition to endometriosis, Orilissa (elagolix), developed by Neurocrine and licensed to Abbvie, is in Phase III for treating heavy bleeding associated with uterine fibroids.
AbbVie's Got A Competitive Edge With Elagolix For Women With Uterine Fibroids
AbbVie announced positive data from the first of two pivotal Phase III studies testing the GnRH receptor antagonist, but Allergan and Myovant are among the companies also looking to bring new drugs to market.
Abbvie’s Elagolix Looks Set To Stake Claim In Endometriosis
Abbvie plans 2017 filing for elagolix, licensed from Neurocrine, after second Phase III trial leaves the oral drug with a competitive profile.